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Although cyclosporin A is a highly effective treatment for 
several skin disorders, particularly psoriasis, its use in derma-
tology appears limited due to drug-induced hypertension and 
nephrotoxicity. Newer, similar-acting anti- T-cell agents 
such as FK-506 and rapamycin may be more effective; there-
fore a comparison was made with cyclosporin A to assess their 
inhibitory action on T-cell responses and keratinocyte pro-
liferation. Using a guinea-pig model of delayed-type hyper-
sensitivity to dinitrofluorobenzene (DNFB), drugs were 
given systemically (25 mg/kg cyclosporin A, rapamycin; 2.5 
mg/kg FK-506) and topically (0.02% and 2%) at the time of 
DNFB challenge or several hours after and were assessed 
with respect to erythema and the numbers of infiltrating T 
lymphocytes entering skin-challenge sites. FK-506, at all 
concentrations, significantly inhibited both T-cell infiltra-
tion and skin reddening when used by both routes. Rapamy-
Systemic cyclosporin A (CyA) has proved effective in the treatment of psoriasis, a putative autoimmune disease, and other candidate dermatoses displaying similar T -lympho-cyte involvement [1 ,2). Yet despite this, its use is restricted to severely affected patients because of drug-induced hy-
pertension and nephrotoxicity. This, compounded with the diffi-
culty in producing a completely clinically effective topical CyA 
preparation [3 - 5), suggests that its future use in dermatology, at 
least, may remain limited. Despite these problems, the testing of 
other similar-acting drugs such as FK-506 (FK) and rapamycin 
(RPM) is warranted; they may be less toxic than CyA or display 
greater topical efficacy. 
Both FK and RPM are hydrophobic macrolide antibiotics; how-
ever, their sub-cellular actions are distinct. In common with the 
cyclic undecapeptide CyA, but at concentrations 10-100 times less, 
FK selectiv~ly suppresses the activation of CD4+ cells by inhibiting 
the expreSSIOn of early T -cell- activating genes encoding the cyto-
kines interieukin(IL)-2, IL-3, IL-4, tumor necrosis factor alpha 
(TNFa), and interferon-gamma (IFNI') (6.7). In contrast, RPM, 
which inhibits T - and B-cell activation, is a more potent inhibitor of 
T -cell proliferation than CyA [8,9). Unlike FK and CyA it does not 
prevent cytokine synthesis, but inhibits cytokine-mediated signal 
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cin displayed no inhibitory effect, whereas cyclosporin A 
only suppressed the erythema response when given systemi-
cally. The inhibition of normal human keratinocyte growth 
by the drugs was assessed using a protein dye-binding assay. 
After 2 weeks, FK-506 had no effect, whereas cyclosporin A 
and rapamycin both inhibited keratinocyte growth in a dose-
dependent fashion and almost equivalently in serum-con-
taining and serum-free keratinocyte growth medium. The 
findings showed that in vivo only FK-506 suppressed T-cell 
involvement in sensitized animals. In contrast, it failed to 
have any effect on keratinocyte growth, whereas rapamycin 
was more potent than cyclosporin A in inhibiting their pro-
liferation. The future benefit of these drugs in dermatology 
may ultimately lie in their combined use. Key words: cyclo-
sporin A/FK-506/rapamycinjdelayed-type hypersensitivity and 
keratinocytes. ] Invest Dermatol 102:84 - 88, 1994 
transduction as demonstrated by its inhibitory action upon the pro-
liferation of IL-2, IL-4, and IL-6 lymphokine-dependent cell lines 
[10,11]. Recent work suggests that RPM interferes with the intra-
cellular incorporation of the IL-2jreceptor complex, because nei-
ther the expression nor the avidity of IL-2 receptor binding sites is 
diminished by the drug [8) . 
Clinically, FK represents a potent immunosuppressive agent, 
particularly in liver transplantation, and may prove superior to CyA 
by virtue of successfully reversing acute ongoing liver rejection 
[12,13). Currently its potential value in the treatment of T-cell-
dependent autoimmune conditions such as uveitis, nephrotic syn-
drome, and also psoriasis is being evaluated [14]. In contrast, clinical 
trials with RPM have only recently begun following its effective 
suppression of experimental organ rejection and autoimmune dis-
eases [8,15,16]. Clearly the contrasting effects in potency and sub-
cellular action of these novel immunosuppressive agents suggest 
their possible usefulness in the treatment of diseases such as psoria-
sis, which displays both active T-cell involvement and altered ke-
ratinocyte responsiveness to growth regulatory cytokines (17,18]. 
This study was performed to compare the efficacy ofFK, RPM, and 
CyA in suppressing experimental T-cell-mediated skin reactions 
and inhibiting the growth of cultured human epidermal cells grown 
in serum-free and serum-containing media. 
MATERIALS AND METHODS 
Drugs CyA (Sandoz Ltd, Basle, Switzerland), FK (Fujisawa Pharmaceuti-
cal Company, Osaka, Japan), and RPM (Wyeth-Ayerst Research Laborato. 
ries, Princeton, NJ) were dissolved in a vehicle of 1 0% ethanol (CyA, RPM) 
or methanol (FK) and olive oil (BDH, Poole, Dorset, U .K.) for it/ vivo 
studies. For tissue culture the drugs were disso lved in alcohol that was 
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diluted 1000 times by culture medium. Alcohol-containing control media 
contained 0.1 % ethanol. 
Experimental Delayed-type Hypersensitivity Reactions (DTH) 
Dunkin-Hartley guinea pigs purchased from David Hall, Newchurch, 
Staffs, U.K., weighing 800-1000 g, were sensitized to 1-fluro-2, 4-dinitro-
benzene (DNFB) by epicutaneous application of 50 III 10% (w Iv) DNFB 
solution in acetone: olive oil (1: 1) on the dorsum of one ear. Animals were 
challenged 8 d later by application of a non-irritant dose of 20 III DNFB 
solution (0.5% w/v) in acetone: olive oil (4: 1) to the shaved flank and 
received drugs (25 mg/kg body weight, CyA and RPM; 2.5 mg/kg FK) or 
vehicle (1 ml/kg) systemically by gavage immediately (0 h) or 5 h later 
(+ 5 h). Animals were treated again with drugs 24 h later. Guinea pigs 
receiving topical drugs were challenged as before with DNFB, and immedi-
ately after drying (0 h) they received one appl ication to the test site of topical 
drugs (20 II I of 0.02% or 2% w Iv) or administration was delayed for 6 h 
(+ 6 h). Animals received another application of drugs 6 h later. 
Assessment ofDTH The erythematous reactions in guinea pigs, which 
were given topical and systemic drugs, were assessed "blind" at 24 and 48 h, 
respectively, by cwo independent assessors. Test sites wete scored using the 
following scale: 0, no change; 0.5, feeble reaction; 1, patchy pink spots; 2, 
confluent pink; 3, red but not elevated; 4, red and elevated; 5, red, elevated, 
and ulcerating. 
To assess the extent of inflammatory T-cell infiltration, skin biopsies were 
excised from the center of the reaction sites, snap-frozen, and cryostat sec-
tions (6Ilm) were fixed for 20 min in acetone prior to staining. The three-
stage alkaline phosphatase - anti-alkaline phosphatase method was used to 
demonstrate the pan T-cel l marker on guinea pig T lymphocytes by using 
the primary mouse monoclonal antibody CT7 (Dr. R.J. Scheper, Patholog-
ical Institute, Free University Hospital, Amsterdam, the Netherlands) 
diluted 1: 200 in tris-buffered saline (TBS). Secondary antibody, rabbit 
anti-mouse Igs (Dako, Copenhagen, Denmark) was diluted 1 : 20 in TBS 
containing 10% normal guinea pig serum. An assessment of cellular infiltra-
tion was performed on coded sections by counting positively stained cells in 
the epidermis and upper papillary dermis using a point count method with an 
eyepiece grid. 
Preparation ofKeratinocytes Normal human pediatric foreskins, pre-
viously washed in 10 X strength antibiotics in Dulbecco's modified Eagle's 
medium (DMEM, Gibco, Paisley, Scotland, UK) for 30 min and soaked in 
1 X antibiotic solution (penicillin, 100 u/ml; streptomycin 100 Ilg/ml, and 
including 2.5Ilg/ml amphotericin B; Flow Laboratories, Irvine, Scotland, 
UK) were cut into small pieces and incubated overnight at 4·C in 0.25% 
dispase (Boehringer Mannheim, Lewes, East Sussex, UK) in DMEM. The 
epidermis was peeled from the dermis and incubated for 30 min at 37"C in 
0.125% trypsin in Ca++- and Mg++-free PBS containing 0.02% ethylene-
diamine tetraacetic acid (EDTA; Flow). Trypsin was inactivated by adding 
DMEM + 10% fetal calf serum (FCS; Gibco) and a single-cell suspension 
was obtained by filtering through wire gauze. After washing, keratinocytes 
were resuspended in either low-Ca++ (0.09 mM), serum-free keratinocyte 
medium (SFM; Gibco) supplemented with 5 ng/ml recombinant epidermal 
growth factor (EGF) and 50 Ilg/ml bovine pituitary extract, or in serum-
containing keratinocyte growth medium (KGM) consisting of DMEM: 
Ham's F-12 (Flow) (3: 1), 10% FCS, 1 % antibiotic solution, and the follow-
ing growth factors; 24.3Ilg/ml adenine, 5llg/ml insulin, O.4llg/ml hydro-
cortisone, 10- 10 M cholera toxin, and 5llg/ml transferrin (all Sigma). 
Keratinocyte Culture Primary keratinocyte cultures were established by 
seeding 50 III of cells in 96-well plastic plates (Cel-Cult, Bibby Sterilin Ltd., 
Stone, Staffs, UK) at a density of 1 X 106/ml. Drugs (50 Ill), made up in 
either SFM or KGM, were added at the same time as the cells (day 0). The 
final concentration of drugs was 3, 6, and 10 Ilg/ml for CyA and RPM, and 
10, 100, and 1000 ng/ml for FK. Controls included cells grown in medium 
alone and in the drug vehicle of 0.1 % ethanol in medium. On Day 3, and 
every 3 d thereafter, medium was replaced with drugs and fresh KGM 
containing EGF (10 ng/ml) or SFM. Cultures were incubated at 37"C in a 
5% CO2 atmosphere. 
Measurement of Cell Growth On Days 7 and 14 plates were stained by 
the Coomassie Blue protein staining method [19] and the optical density 
(00) of the stained wells used as a measure of cell growth. Plates were read 
on a Dynatech MR5000 microplate reader at 630 nm wavelength. Six wells 
were used for each treatment to give an average OD value. 
Statistics Statistically significant differences between drug treatments and 
controls were assessed by the Mann-Whitney test for erythema scores and 
rhe Student t test for T-cell infiltrates and keratinocyte growth. 
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RESULTS 
Effect of Drugs on DTH Reactions Results of the inhibition of 
DTH responses in guinea pigs given systemic CyA, FK, and RPM 
are shown in Table 1. Guinea pigs given either CyA or FK at the 
time of (0 h) or 5 h after (+ 5 h) challenge with DNFB displayed 
significantly suppressed erythema reactions in comparison with ve-
hicle-treated animals. Although the intensity of erythema was re-
duced in animals receiving systemic RPM this failed to be signifi-
cant at either time. When biopsies from test sites were examined, 
only guinea pigs that received FK at the time of DNFB challenge 
had significantly fewer infiltrating T lymphocytes compared with 
either vehicle-treated animals or those in which FK was delayed for 
5 h (+5 h). 
The effects of topical application of CsA, FK, and RPM to guinea 
pigs undergoing DTH reactions are shown in Table II. Although 
the intensity of erythema in topical vehicle-treated animals was half 
that of animals given systemic vehicle (Table I), the inflammatory 
T-cell counts were similar, suggesting an unlikely interference of 
the vehicle with absorption of the recently applied DNFB. More 
probabl~, the vehicle prod~ced a direct reduction in epidermal in-
flammatIon, a feature descnbed for several bland emollients [20]. 
Guinea pigs receiving topical 0.2% and 2% FK at the time of 
DNFB challenge (0 h) showed a significant reduction in the inten-
sity of skin reddening when compared with their vehicle, whereas 
only at the higher dose (2%) was there a significant difference in 
erythema between skin sites that received drug at either 0 or 6 h. 
Only those animals given FK topically (0.2% and 2%) at the time of 
DNFB challenge showed a significant reduction in the T-cell in-
flammatory infiltrate. Neither CsA nor RPM displayed any immu-
nosuppressive effects when applied topically at 0 .2 and 2%. 
Inhibition ofKe Growth by Drugs The effects of CsA, RPM, 
and FK on keratinocyte growth il1 vitro are shown in Fig 1. The 
addition of ethanol (0.1 %) to cultures had no effect on their growth 
in either serum-containing KGM or SFM. Both CyA and RPM 
significantly inhibited keratinocyte growth at Days 7 and 14 in both 
media with a dose-response effect being more evident in SFM. At 
each time, in SFM and KGM, 10 ,ugjml RPM produced almost the 
same degree of inhibition of keratinocyte growth as the equivalent 
concentration of CyA; however, at 6 and 3 ,ugjml, RPM was more 
inhibitory than the same concentrations of CsA, although not sig-
nificantly. FK demonstrated no inhibitory effect on keratinocyte 
growth in either KGM or SFM, apart from one concentration (100 
ngjml) in SFM. 
The percentage inhibition of keratinocyte growth in KGM and 
SFM for each drug concentration was compared between Days 7 
and 14. In KGM there was no further reduction in cell growth at 
Day 14 compared with Day 7 for any drugs. In contrast, in SFM 
keratinocytes grown in the presence of CyA showed a further aver-
age reduction in growth at Day 14 compared with Day 7 of 60%, 
which was significant (p < 0.05) at 6,ugjml CsA. By Day 14 RPM 
had produced a further 70% reduction in growth compared with 
Day 7 values, which were significant at 3, 6 (p < 0 .01), and 10 
,ugjml (p < 0.001). 
Keratinocytes grown in medium, the ethanol vehicle, and FK had 
formed an undifferentiated monolayer by Day 14. In comparison, 
10,ugjml CyA and RPM were particularly toxic, as remnants of 
dead cells were most evident by 7 d. Lower concentrations of CyA 
and RPM appeared to have a cytostatic action and produced gross 
abnormalities in cell appearance with 6,ugjml CyA or RPM, and 
3 ,ugjml RPM. 
DISCUSSION 
Cyclosporin A has previously been shown to inhibit significantly 
DTH responses to DNFB in guinea pigs when given systemically 
during the initial period of T-cell sensitization [21]. In contrast, 
when CyA was first administered at the time of antigen challenge to 
murine models of hypersensitivity pneumonitis [22] and DTH to 
methylated BSA [23], the drug failed to prevent the accumulation of 
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Table I. Effect of Systemic Drugs on the DTH Response in Guinea Pig Skin at 48 h After Challenge with DNFBd 
Time of Drug Application after DNFB Challenge (h) 
Dose (w/v) Given Intensity of Erythema Number ofInfiltrating T cells/mm! 
Drug 0+ 24 h n 0 +5 0 +5 
Vehicleb 7 3.2 ± 0.8 3.4 ± 0.8 130 ± 32 140 ± 83 
CyA 25 mg/ml 5 1.5 ± 0.9' 1.7 ± 0.8d 123 ± 43 116 ± 82 
FK 2.5 mg/ml 5 1.5 ± 0.8' 1.7 ± 0.9' 32 ± 9'.J 84 ± 36 
RPM 25 mg/ml 5 2.2 ± 0.8 2.7 ± 0.8 117 ± 47 99 ± 101 
• Intensity of erythema was scored visually and the number of infiltrating T cells enumerated on biopsy sections. Results represent means ± SD from three experiments. 
6 Statistically significant differences between drug and vehicle for each time ('p < 0.05; 'p < 0.01; 'p < 0.001) and berween times for each treatment (fp < 0.05) were measured 
using the Mann Whitney test for scores and Student t test for cell counts. 
inflammatory cellular infiltrates although accompanying increases 
in lung volume and fluid exudates, respectively, were inhibited. 
Similarly, in this study, when systemic Cy A (25 mg/kg) was given 
at the time ofDNFB challenge or 5 h later, it significantly inhibited 
erythema, but there was no suppression of the T -cel l response. 
Whereas systemic CyA appears to be ineffective in suppressing the 
participation of previously sensitized T cells, of which many will be 
specific skin-residing memory T cells [24J, its ability to suppress the 
accompanying erythema suggests that these manifestations may not 
be entirely T cell mediated. These irritant-like features, character-
ized by increased vascular permeability and edema, may in fact result 
from the binding of haptens directly with KC, which induces their 
activation and release of inflammatory cytokines such as TNFa, 
granulocyte-macrorhage colony-stimulating factor (GM-CSF), 
IL-1, and IL-8 [25 . Evidence suggests that TNFa plays a central 
role in this response because anti-TNFa monoclonal antibodies 
totally abolished ear thickening during contact sensitivity responses 
in challenged mice [26]. Therefore, given that CyA can inhibit 
TNFa release from mononuclear leukocytes [22,27], and may also 
suppress KC-derived TNFa production [28], this might account for 
its effective suppression of erythema but not the accompanying 
cellular infiltrate. 
[n contrast to its effects when given systemically, topical Cy A at 
0.02 and 2% did not prevent any aspect of the DTH response in this 
study although previously it has been particularly inhibitory at 5% 
[29) . It is likely, therefore, that 2% CyA was an insufficient concen-
tration to provide effective immunosuppression. 
Unlike CyA, FK was most potent at suppressing challenge DTH 
reactions. Not only did it inhibit erythema when given systemically 
at one-tenth of the concentration used for CyA, but it also signifi-
cantly suppressed the accumulation of T cells at test sites by 75% 
when given at the time of challenge and partially (40%) , but not 
significantly, when delayed by 5 h. This superior immunosuppres-
sive efficacy shown by FK has previously been demonstrated fol-
lowing its administration to guinea pigs with ongoing uveitis where 
the development of eye damage and antibodies to retinal S-antigen 
was suppressed [30]. Although FK may primarily inhibit sensitized 
or activated T cells, it also impairs alloantigen presentation by mon-
ocytes [31] and might similarly affect antigen handling by Langer-
hans cells . 
The most important observation from this in vivo study was that 
FK was extremely effective when used topically. This agrees with 
recent findings by Meingassner and Stutz, who examined vascular 
changes in pigs undergoing DTH reactions to DNFB and found 
that neither CyA (10%) nor RPM (0.13 and 1.2%) suppressed skin 
reddening, whereas concentrations of 0.04 -0.4% FK were all in-
hibitory [32]. In the guinea pigs even concentrations as low as 
0.02% significantly suppressed erythema and, more importantly, 
the inflammatory infiltrate by 60%. Interestingly, RPM failed to 
inhibit any aspect of the DTH response when given topically or 
even systemically. Rapamycin does not inhibit the expression of 
early activation genes, as do FK and CyA, but instead doubles their 
transcripts in activated T cells [7] . If RPM induced similar elevations 
of inflammatory cytokines in hapten-stimulated keratinocytes, then 
this might provide the inflammatory stimulus responsible for main-
taining the DTH response. 
Rapamycin was particularly potent at suppressing the growth of 
normal human keratinocytes and exceeded that of equivalent con-
centrations of CyA (3 -10 ,Ltg/ml), which are reportedly present in 
psoriatic epidermis (1-2.9 tlg/mJ) of systemically drug-treated pa-
tients [33]. The inhibitory action of 10 ,Ltg/ml RPM and CyA was 
undoubtedly due to drug toxicity, whereas lower concentrations 
(3 and 6,Ltg/ml) appeared to have a cytostatic action. Unlike CyA 
and RPM, FK, even at 1 ,Ltg/ml, had no inhibitory effect on cell 
growth. In this study the effects of each drug on the growth of 
keratinocytes were similar in both serum-free or -containing media; 
serum did not diminish the inhibitory effects of CyA or RPM. 
The mechanism(s) by which RPM and CyA, but not FK, induces 
this growth inhibition is not known. Normal cultured keratinocytes 
have been reported to express reduced numbers of functional epi-
Table II_ Effect ofTopica\ Drugs on the DTH Response in Guinea Pig Skin at 24 h After Challenge with DNFBd 
Time of Drug Application after DNFB Challenge (h) 
Dose (w/v) Given 
Numbcr of Infiltrating 
Intensity of Erythcma T cells/mm! 
Drug 0+6h n 0 +6 0 +6 
Vehicle 6 1.7 ± 0.8 1.3 ± 0.5 131 ± 62 120 ± 58 
CyA 2% 6 
(n = 12) 
1.3 ± 0.4 
(n = 12) 
1.9 ± 0.6 126 ± 73 108 ± 33 
0.02% 6 1.3 ± 1.0 1.2 ± 0.3 135 ± 77 145 ± 47 
FK 2% 6 0.5 ± 0.6b•d 1.3 ± 0.4 54 ± 60b 63 ± 45 
0.02% 6 0.8 ± 0.8b 1.2 ± 0.3 52 ± 34' 106 ± 74 
RPM 2% 6 1.0 ± 0.6 1.5 ± 0.9 98 ± 62 141 ± 75 
0.02% 6 1.3 ± 0.9 1.5 ± 0.6 145 ± 108 174 ± 80 
• Intensity of erythema was scored visually and the number of infiltrating T cells enumerated on biopsy sections. Results represent means ± SD from two experiments. 
Statlstlcally Slgmficant dlfferences between drug and vehlcle for each time (6p < 0.05; 'p < 0.01) and between times of drug administration ('p < 0.05) for each treatment wert 
measured using the Mann-Whitney test for sCores and Student t test for cell counts. 
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Figure 1. Drug effects on keratinocyte growth. Primary epidermal ce lls were grown in the presence of serum-containing medium (KGM) or serum-free 
medium (SFM) and drugs; medium (Med), ethanol control (EtOH), 3 - 10 Ill/ ml eyA and RPM, and 10-1000 ng/ ml FK. On Days 7 and 14 cell growth in 
control and drug treatment groups was expressed as a percentage of cells grown only in medium. Columlls, percentage mean ± SD from at least 5 individual 
skins. Statistically significant inhibition of cell growth by drugs was assessed by comparing drug treatments with their ethanol control; "p < 0.001 , 'p < 0.01, 
+p < 0.05. 
dermal growth factor receptors (EGFRs) following CyA treatment, 
despite producing increased amounts of its ligand-transforming 
growth factor alpha (TGFa) [34] . In addition, keratinocyte growth 
driven by basic fibroblast growth factor, another keratinocyte auto-
crine growth factor that mediates its effects via a receptor distinct 
from EGFR, is also affected by CyA (35). To the same extent, RPM 
has also been shown to diminish the autonomous £roliferation of 
T-cell hybridoma cells [10) and rat hepatocytes [36J, where in the 
latter mRNA transcripts of their growth factor, TGF-beta, but not 
of non - growth-associated proteins such as albumin, were inhib-
ited. It is possible that this non-immunologic inhibition of cell 
growth results from the blockade by CyA and RPM of their cytoso-
lic binding proteins (BP), which may regulate cell growth in a 
manner similar to the FK-BP, which has recently been shown to 
promote hepatocyte growth in vivo [37) . 
Initial clinical assessment with FK suggests that systemic FK may 
be a more potent drug than CyA for the treatment of psoriasis; 
complete remission occurred within 4 weeks and persisted, but this 
was accompanied by some renal impairmen t [38]. As FK does not 
appear to affect the growth of keratinocytes, its anti-psoriatic prop-
erties possibly result primarily from an inhibitory action on T cells 
rather than on keratinocytes. This has been evidenced by the rapid 
disappearance of inflammatory infiltrates from psoriatic plaques, 
which well preceded any resolution of hyperkeratosis in the skin of 
FK-treated patients [38] . The experimental results of its use topi-
cally in this study do, however, indicate that FK either has a greater 
therapeutic index than CyA or better percutaneous penetration 
properties and, therefore, warrants fuller examination as a topical 
preparation. The long-term aim of producing an effective but non-
toxic drug regime for treating dermatoses such as psoriasis may 
ultimately depend upon drug combination therapy. Recently, CyA 
and RPM, at doses that were individually noninhibitory have in 
combination acted synergistically by totally preventing rat cardiac 
allograft rejection [11) . This experimental approach might have 
some practical application to the treatment of psoriasis itself, espe-
cially because CyA is already known to be effective but at essentially 
nephrotoxic concentrations, and RPM displayed such potent 
growth-regulatory effects on keratinocytes. Although the future 
and more widespread use of these specific immunosuppressive drugs 
will ultimately be determined by their toxicity profiles, it is possible 
that individually CyA, FK, and RPM may provide a greater under-
standing of the pathologic mechanisms underlying certain dermat-
ologic diseases. 
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